Article
Results of the MAXIMISE trial show that Secukinumab provided clinical improvement and reduction in inflammatory MRI lesions in patients with psoriatic arthritis and axial disease through week 52.
All News
Dr. Antoni Chan
Tweet
Another interesting study demonstrating the use of ultrasound to assess psoriatic arthritis. In very early, DMARD naïve PsA, clinically swollen joints are associated with PD synovitis, but tender, non-swollen joints are not @RheumNow #ACR20 Abst#313
Mrinalini Dey
Tweet
Following promising data presented at today's poster session, results from RELIEF #Behcets study show #apremilast leads to ↓ rates of new/recurrent/worsening oral ulcers, skin lesions & #arthritis compared to placebo at 12wks.
Abs#0512 #ACR20 @RheumNow
https://t.co/O1dstY5WlL https://t.co/0djnUGw0Hg
k dao
Tweet
Another study on rheum pt outcomes w/#COVID19: similar outcomes as nonrheum pts. MGH/JHU/Brigham 143 rheum vs 688 nonrheum. No⬆️risk in rheums after adjusting for race/smoking/comorbidities for: hospitalizations, mech ventil'n 3. ICU 4. death #ACR20 Abstr#L01 @RheumNow https://t.co/362UZUe5dg
Richard Conway
Tweet
Prof Hatemi report on apremilast in Behcets disease. We know it improves oral ulcers. Now shown to improve skin lesions and arthritis. @rheumnow #ACR20 Abstr#512 https://t.co/BwIqio6dzq
Robert B Chao, MD
Tweet
DISCOVER-2 (52 wk study) Guselkumab 100mg q4wk and q8wk for tx of PsA 1️⃣Sustained responses in: ACR20/50/70, PASI90/100, HAQ-DI, MDA/VLDA, QoL 2️⃣Improvement enthesitis/dactylitis 3️⃣No increase rate of serious infection @RheumNow #ACR20 Abs#0506 https://t.co/7MXYTucVZ9
Dr. Antoni Chan
Tweet
The presence of fibromyalgia in psoriatic arthritis correlates with the clinical outcome scores. Ultrasound evaluation can be useful to evaluate disease activity in the presence of fibromyalgia @rheumnow #ACR20 Abstr#315 #ACRbest
Dr. Rachel Tate
Tweet
“Rheumatology comes in as the #2 specialty utilizing teleheath in a survey by Doximity.” Dr. C. Peoples discussing teleheath and COVID-19. “The elephant in the room is the physical exam!” #ACR20 @RheumNow
Eric Dein
Tweet
How do you treat ACPA+, subclinical synovitis (US/MRI+)? Abst#0481 reviews 3 cohorts for progression to clinical inflam arthritis. 44-68% did not progress to IA in 1 year, is DMARD over treating? #ACR20 #ACRBest @RheumNow
Dr. Rachel Tate
Tweet
Dr. Phillips touches on a few things to consider how teleheath has changed the delivery of care due to COVID-19. Planning your post-pandemic business strategy, due demand for our specialty, is important. #ACR20 @RheumNow https://t.co/A2dsVy1KSg
k dao
Tweet
Dr. C Mohan @UTSWNews #ACR20 @rheumnow reviews IFN in SLE:
👉Diff't IFN assc w/diff't lupus manifestions
👉⬆️stim endosomal DNA/RNA sensors RLR7,8,9 may drive SLE
👉TLR7 & 9 in B cells impt for germinal ctrs & Ab prod’n
👉TLR7 is X-linked
👉IFNsig not track w/dz activity https://t.co/3KK3UvH8Ka
Dr. Antoni Chan
Tweet
The synovio-entheseal complex theory is proposed in the pathogenesis of psoriatic arthritis. The ultrasound study showed a link in the severity of the sonographic findings in the joints and the entheses supporting this model @rheumnow #ACR20 Abstr#311
Eric Dein
Tweet
Sustained remission is rare, should we settle for sustained low disease activity? Abst#0480 ESPOIR Cohort says no, get remission if possible for better radiographic (Sharp) and fxnal (HAQ) scores. Maybe perfect isn't enemy of good? @RheumNow. #ACR20 https://t.co/QNQn9n27rm
Richard Conway
Tweet
Dr Alba reports that in GCA angiotensin II system appears to be activated. Losartan reversed changes and reduced inflammatory markers. Possible role in GCA treatment? @rheumnow #ACR20 Abstr#510 https://t.co/IPp3lD1BUH
Janet Pope
Tweet
Early RA pts may develop chronic widespread pain. Not all have fibromyalgia. Multiple areas of pain & inflammation ^ chronic pain & other factors ie women high initial pain longer symptoms @CRASCRRheum @RheumNow #ACR20 abstr#187 1/3 at onset have regional pain 1/4 at 1yr https://t.co/7qOxH4h7Dd https://t.co/IFO1uwyR0o
Richard Conway
Tweet
Dr Ferrada and colleagues assess relapsing polychondritis cohort for VEXAS. Prevalence of 8%. Male sex or age at onset >50 + MCV >100 + platelet count< 200 classified between VEXAS and RP with 100% sens and 96% spec @rheumnow @petercgrayson #ACR20 Abstr#509 #ACRbest https://t.co/5QMu4Y6xSH
Mrinalini Dey
Tweet
Highlighting results from @rheum_covid at #ACR20
Race/ethnicity Associated with Poor Outcomes in #RheumaticDisease Patients with #COVID19 by @MilenaGianfran et al
Abstract #0006👉https://t.co/13jsl8BjcH
Full paper👉https://t.co/Qeo0dOoIOQ
@RheumNow
https://t.co/U9cgaYYaOj
Bella Mehta
Tweet
#ACR20 keynote Infectious disease Dr Eric Rubin @NEJM EIC answers questions about medications, immunity and vaccines in #COVID19. Many post covid inflammatory symptoms but not sure if its because of background autoimmunity. Need more data. More to come in a few months @RheumNow
Bella Mehta
Tweet
#ACR20 Basic Science Year-in-review Really important work by @danaorange showing PRIME cells can predict flares in #RheumatoidArthritis patients #HSSrheum @RheumNow
https://t.co/XTqqinAN2a https://t.co/24HkqgHS0H
HSS Physician-in-Chief
Tweet
Proud of #HSSRheum! Check out the full list of our 76 Abstracts and 27 moderator and speaker sessions at #ACR20 Convergence here: https://t.co/OoQSzoRxGq. Special congratulations to our two awardees - Roberta Horton and Dr. Jane Salmon! https://t.co/cDkzgFtEH3
